IRA impact: AstraZeneca and Merck CEOs warn of oncology drug development shifts
This latest quarterly earnings season for pharma has been a time for companies to vent about President Biden’s new drug price negotiation law, with some companies like Alnylam pointing to orphan drug designation restrictions, and others like Eli Lilly noting the disparities between small and large molecule drugs when it comes to when the negotiations kick off (9 years vs. 13 years).
But AstraZeneca and Merck executives are now raising concerns about how the IRA will impact cancer drug development moving forward as the clock for negotiations begins with the first approved indication.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.